Moderna, Inc.
MRNA Healthcare Biotechnology
Moderna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024. In the quarter to June 2026, revenue grew 2.11%, EPS grew 7.51%, free cash flow grew 38.9% and total debt rose 1,765.6%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100.
Follow MRNA
Moderna, Inc. (MRNA) Total debt
Moderna, Inc.'s total debt at the end of fiscal 2025 was $610.0M, up 1,464.1% from $39.0M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $597.0M. Over the past ten years it has ranged from $13.0M (fiscal 2016) to $912.0M (fiscal 2022); the current reading is higher than 90% of that period. Moderna, Inc. ranks 24th of 588 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $610.0M | 1,464.10% |
| FY2024 | $39.0M | (93.22%) |
| FY2023 | $575.0M | (36.95%) |
| FY2022 | $912.0M | 52.25% |
| FY2021 | $599.0M | 444.55% |
| FY2020 | $110.0M | 184.32% |
| FY2019 | $38.7M | 17.24% |
| FY2018 | $33.0M | 106.25% |
| FY2017 | $16.0M | 23.08% |
| FY2016 | $13.0M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $597.0M | (1.00%) |
| Mar 2026 | $603.0M | (1.15%) |
| Dec 2025 | $610.0M | 2,246.15% |
| Sep 2025 | $26.0M | (18.75%) |
| 23 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| RPRX Royalty Pharma PLC compare | $9.0B |
| REGN Regeneron Pharmaceuticals, Inc. compare | $2.0B |
| RVMD Revolution Medicines, Inc. compare | $1.0B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $1.0B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $882.2M |
| MRNA Moderna, Inc. | $597.0M |
| ROIV Roivant Sciences Ltd. compare | $323.7M |
| VRTX Vertex Pharmaceuticals Incorporated compare | $111.4M |
| ARGX argenex SE compare | $7.6M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on MRNA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement